Content area
Full text
NEW YORK, Sept. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
EpiCast Report: Acne - Epidemiology Forecast to 2022
http://www.reportlinker.com/p01623034/EpiCast-Report-Acne---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
EpiCast Report: Acne - Epidemiology Forecast to 2022
Summary
Acne vulgaris (acne) is an inflammatory skin disease that affects nearly all adolescents and adults at some point in their lives. The clinical presentation of acne ranges from a mild comedonal form to severe inflammatory cystic acne of the face, chest, and back. Globally, acne has a lifetime prevalence of over 90% in people of all ages, and a point-prevalence of approximately 85% in the population ages 15-24 years.
GlobalData's epidemiological analysis forecasts an increase in the total prevalent cases of acne in people ages 10-44 years in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK), from 103.91 million prevalent cases in 2012 to 105.46 million prevalent cases in 2022, with a decadal growth rate of 1.5%. As GlobalData epidemiologists used steady prevalence proportions of acne over the forecast period, the growth in prevalent cases in each market can be attributed to the change in population demographics in people ages 10-44 years in the respective markets.
Although acne is not a life-endangering condition, it is associated with a huge psychosocial impact and economic burden. GlobalData's epidemiological forecast emphasizes the need for preventive measures that are directed towards...